- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02469402
Nutritive Efficacy and Safety of a Modified Infant Formula With a Reduced Protein Content and Improved Protein Quality
Nutritive Efficacy and Safety of a Modified Infant Formula With a Reduced Protein: Content and Improved Protein Quality: LactPro-Minus
Formula contains significantly higher total protein concentrations than breast milk. Therefore formula-fed infants have a significantly higher total protein intake in the first few months compared to exclusively breast-fed infants.
The aim is to examine the nutritive efficacy and safety of a modified infant formula with a reduced protein content and improved protein quality in a prospective, double-blind, controled, randomized study. Primary outcome measures are weight gain and growth of young infants under 12 weeks of dietary intake of the new infant formula. Metabolic effects of the qualitative and quantitative changes in the protein content of the new formula will be recorded. Two groups of healthy bottle-fed infants will be compared. The treatment group will be fed for 3 months with an infant formula with decreased protein content. At the same time the protein body of the new formula is modified by enrichment with bovine alpha-lactalbumin.
A control group receives a isocaloric conventional infant formula and a protein body consisting of whey protein and casein in a ratio of 60:40, without specific accumulation of alpha-lactalbumin over the same time-period.
A group of breastmilk fed infants will serve as a reference group. In regular anthropometric controls growth and thriving of the study participants is documented and compared between the different groups.
Study Overview
Status
Conditions
Detailed Description
Breast milk is considered the gold standard for early childhood nutrition, it is optimized in terms of ingredients to the needs of the infant in the first months of life. Formula differ in many ways in their composition to breast milk, e.g. in the structure and concentration of the protein contained.
To ensure adequate supply of the infant with all essential and semi-essential amino acids conventional infant formula contains significantly higher total protein concentrations than breast milk. Therefore formula-fed infants have a significantly higher total protein intake in the first few months compared to exclusively breast-fed infants, and individual amino acids are therefore fed in excess.
The increased intake of protein, and thus the increased intake of some insulinogenic amino acids in infancy (e.g. the branched chain amino acids leucine, isoleucine and valine), is now considered as a possible co-factor for later disposition to overweight and obesity. Breastfeeding induces slower growth of the infant and is proven to be associated with a lower risk of being overweight or obese at the time of school entry (von Kries 1999). The higher protein intake in bottle-fed babies seems to contribute significantly to the differences that can be observed in the growth behavior between breast-fed and bottle-fed children in the first years of life.
Obvious approaches to optimize infant formula are therefore the reduction of protein content, while ensuring an adequate supply of all relevant amino acids similar to breast milk.
Enrichment with alpha-lactalbumin enables the reduction of total protein content in the formula through the qualitative upgrading of the protein body and the high content of essential amino acids, thereby limiting a surplus of protein intake, but at the same time to supply adequate amounts of essential amino acids.
The aim is to examine the nutritive efficacy and safety of a modified infant formula with a reduced protein content and improved protein quality. Primary outcome measures are weight gain and growth of young infants under the 12 weeks of dietary intake of the new infant formula, and metabolic effects of the qualitative and quantitative changes in the protein content of the new formula. Two groups of healthy bottle-fed infants will be compared. The treatment group will be fed for 3 months with an infant formula with decreased protein content. At the same time the body of experimental protein infant formula was modified by enrichment with bovine alpha-lactalbumin.
A control group receives a isocaloric conventional infant formula and a protein body consisting of whey protein and casein in a ratio of 60:40, without specific accumulation of alpha-lactalbumin over the same time period.
A group of breastmilk fed infants will serve as a reference group.
In regular anthropometric controls growth and thriving of the study participants is documented and compared between the different groups. In addition, laboratory tests are carried out, which will examine the influence of diet on insulin response, protein metabolism and specific growth factors.
In a follow-up long-term effects of nutrition on body composition will be recorded by comparing body fat measurements (skinfold thickness-Calipometrie) during the first year of life.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 13589
- Evangelisches Waldkrankenhaus Spandau
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- At the time of study enrollment apparently healthy newborns / infants without pronounced hyper- or hypotrophy (age-appropriate weight percentiles > 3 and < 97 according to Voigt et al.)
- Maternal decision against breastfeeding (for Formula Groups)
Exclusion Criteria:
- Congenital gastrointestinal malformations, metabolic disease, chromosomal aberration, syndromic disease with significant impact on growth, development, nutrition, immune competence
- Manifestation of a serious disease, which is expected to be accompanied by growth retardation, intestinal transit disruption or the need for special dietary treatment (e.g. hypertrophic pyloric stenosis, cystic fibrosis, Hirschsprung's disease, cow's milk protein intolerance.)
- Decision to administer HA (hypoallergenic) formula due to family atopies (defined by atopic disease of at least one 1 st degree relative: bronchial asthma, atopic dermatitis, pollinosis)
- Participation in another nutritional study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Standard infant formula
|
|
|
No Intervention: Breast-feeding
Exclusive breast-feeding
|
|
|
Experimental: Protein reduced formula
Protein reduced alpha-lactalbumin formula
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Composite measure of Growth
Time Frame: 1 year
|
height, body weight, head circumference
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Daily fluid intake
Time Frame: 3 months
|
ml/kg/d
|
3 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Plasma concentrations of transthyretin, urea and total protein
Time Frame: 3 months
|
3 months
|
|
|
Body Fat Percentage
Time Frame: 1 year
|
skinfold thickness-Calipometrie
|
1 year
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Frank Jochum, Dr. med., Paul Gerhard Diakonie
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1026
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overweight
-
National University Health System, SingaporeActive, not recruitingObesity | Overweight and/or Obesity | Overweight or Obese Adults | Overweight , ObesitySingapore
-
Carmen Lucas AbellánUniversidad Católica San Antonio de MurciaCompletedOverweight/Obesity | Overweight or Obese | Overweight or Obese Adults | Obesity and Overweight | Obese SubjectsSpain
-
Empros Pharma ABNot yet recruitingOverweight or Obese | Obesity and Overweight
-
University of AarhusThe Danish Dairy Research Foundation, Denmark; Sygekassernes HelsefondCompletedOverweight and Obesity | Overweight Adolescents | Metabolic DiseaseDenmark
-
University Hospital Bispebjerg and FrederiksbergUniversity of CopenhagenCompleted
-
Children's Hospital Los AngelesEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingOverweight and Obesity | Overweight AdolescentsUnited States
-
University Hospital, LilleNational Research Agency, France; European Union; University of Lille Nord de... and other collaboratorsActive, not recruitingOverweight and Obesity | Overweight, Childhood | Overweight, InfantFrance
-
Holbaek SygehusUniversity of Copenhagen; University of Florida; University of Minnesota; Hebrew... and other collaboratorsRecruitingChildhood Overweight and ObesityDenmark
-
Medialis Ltd.RecruitingObesity & Overweight | Overweight (BMI > 25)United Kingdom
-
Federal University of Health Science of Porto AlegreCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.Active, not recruitingObesity & Overweight | Overweight (BMI > 25)Brazil
Clinical Trials on Standard infant formula
-
Société des Produits Nestlé (SPN)Completed
-
Société des Produits Nestlé (SPN)University College, LondonCompletedGrowth | Infant FormulaUnited Kingdom
-
Biostime (Guangzhou) Health Products LimitedBioFortis; Merieux NutriSciences (China)Active, not recruiting
-
Laboratorios OrdesaUnknownInfant DevelopmentSpain
-
Ludwig-Maximilians - University of MunichHiPP GmbH & Co. Vertrieb KGCompletedInfant NutritionGermany, Serbia
-
FrieslandCampinaTerminated
-
NestléNational University Hospital, SingaporeCompleted